Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
24 results
D2.308 - Diet quality and intake behaviours among alpha-gal–positive patients at a specialized allergy clinic in Sri Lanka
D2.317 - “Cutaneous Anaphylaxis to Raw Egg White in a Patient with Established Oral Tolerance: Clinical Evidence Supporting the Dual-Allergen-Exposure Hypothesis”
D2.318 - Don`t miss the cannabis-associated food syndrome (CAFS)
D2.303 - The effect of extrusion on the in vivo allergenicity of pistachio and walnut in allergic children
D2.304 - Allergy and Exercise: A Sporting Challenge
D2.305 - Alpha-gal syndrome
D2.306 - From baked cookie to unheated milk: Desensitization in a high-risk cow’s milk protein allergy patient
D2.307 - Parental and Healthcare Professional Experiences of Food Allergen Introduction during Complementary Feeding: A Behavioural Theory–Informed Systematic Review
D2.309 - HAL-MPE1, a novel subcutaneous immunotherapy candidate for peanut allergy. Phase I randomized placebo-controlled study
D2.313 - Scientific Evidence Gaps in FAO/WHO Food Allergen Threshold Guidance: Implications for Risk Assessment and Regulatory Decision-Making
D2.315 - Clinical Characteristics and Diagnostic Challenges in Pediatric Peanut and Tree Nut Allergies: The Impact of Unnecessary Elimination
D2.316 - Novel Homozygous Mutation in CARD11 gene Predisposing To Recurrent Infections and Atopies, and Response to Immunoglobulin therapy
D3.440 - Long-Term Efficacy and Safety of Donidalorsen for Hereditary Angioedema Among Patients in Europe: A Regional Analysis of the OASISplus Study
D3.441 - Switching to Donidalorsen for Hereditary Angioedema: 1-Year Results From the Phase 3 OASISplus Study
D3.444 - Efficacy and Safety of Donidalorsen for Patients With Hereditary Angioedema in Europe Who Switched From Prior Long-Term Prophylaxis: Results From the OASISplus Study
D3.445 - Validation of a Novel Serum-Based Indirect Basophil Activation Test (iBAT) to Evaluate Efficacy of a Pivotal Phase III PQ Grass Immunotherapy Trial
D3.437 - Impact of benralizumab on fatigue and health-related quality of life in patients with hypereosinophilic syndrome: findings from the NATRON phase 3 trial
D3.438 - Clinical outcomes with navenibart according to baseline attack rate, body mass index, and age: results of the ALPHA-STAR trial
D3.439 - Donidalorsen For The Treatment Of Hereditary Angioedema: 1-Year Results From The OASISplus Open-Label Extension Cohort
D3.442 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Open-Label Extension Cohort
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download